E. Curti

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

L. Cascione, D. Rossi, A. Stathis, 2019, Haematologica.

with other anti-lymphoma targeted agents The BTK inhibitor zanubrutinib ( BGB-3111 ) demonstrated synergies Version 2 HAEMATOL / 2018 / 214759 Haematologica Bertoni

L. Cascione, D. Rossi, A. Stathis, 2019 .